The mammalian Ras proteins, H-, N-and K-Ras, belong to the small GTPase superfamily. They cycle between a GTP-bound active form and a GDP-bound inactive form.
Therefore, G12 and G13 mutations are less activating than Q61 mutations. In human cancers with NRAS mutations, G12 mutations are prevalent in myeloid leukemia, whereas Q61 mutations are predominant in plasma cell myeloma and melanoma (Supplementary Figure S1A) . In hematopoietic malignancies,~70% of NRAS G12 mutations are identified in patients with myeloid diseases, but these mutations are rare in those with plasma cell myeloma (Supplementary Figure S1B) . In contrast, the incidence of Q61 mutations is equal in patients with myeloid leukemias or plasma cell myeloma (~40% each; Supplementary Figure S1B ). Of note, the acquisition of two copies of oncogenic NRAS G12D or G13D alleles is associated with JMML/CMML progression in humans and mice (COSMIC database (http://cancer.sanger.ac.uk/cosmic) and Kong et al. 4 ), indicating that incremental activation of Ras signaling is a pathological mechanism contributing to JMML/CMML development. In a recent study of mutation-specific Nras oncogenicity, only an endogenous Nras Q61R mutation could promote spontaneous melanoma formation in mice. 5 However, the ability of endogenous Nras G12D and Q61R mutants to drive leukemogenesis has never been evaluated in a side-by-side comparison.
We and others previously showed that expression of one or two copies of oncogenic Nras G12D (Nras G12D/+ and Nras
G12D/G12D
) in the hematopoietic compartment induces a chronic or an acute myeloproliferative neoplasm (MPN) respectively, closely resembling human JMML/CMML. [6] [7] [8] [9] Here we used the same interferoninducible Mx1-Cre to generate Nras Q61R/+ and Nras
Q61R/Q61R
mice (see details in Supplementary Methods). To our surprise, Nras Q61R/Q61R mice were not found at the time of weaning, likely due to the leaky expression of Nras Q61R on the paternal parent side, which was more detrimental than that of the equivalent Nras G12D allele (Supplementary Table S1 ). Therefore, our entire study focused on the comparison among Nras and Nras G12D/G12D animals.
After the induction of oncogenic Nras expression using polyinosinic-polycytidylic acid injections (Supplementary Figure S2A) , we evaluated the levels of GTP-bound Ras isoforms in total bone marrow cells (Figure 1a) . Consistent with our previous results, 6 Nras-GTP level moderately, but significantly, increased in Nras G12D/+ cells compared with that in control cells (Figure 1a Figure S5C) . Increased proliferation was only significant in Nras Q61R/+ and Nras
G12D/G12D
MPs, but not in Nras G12D/+ MPs (Figure 2b) . Colony-forming assays demonstrated that in the absence of cytokines or in the presence of murine interleukin-3 (mIL-3) or murine granulocyte-macrophage colony-stimulating factor (mGM-SCF), Nras and Nras G12D/G12D bone marrow cells formed incrementally increased number and size of colonies (Figure 2c and Supplementary Figure S6 ). Together, the MP phenotypes in Nras G12D/+ , Nras Q61R/+ and Nras G12D/G12D mice are highly consistent with the increasing severity of MPN phenotypes found in these mice.
To determine whether the expansion of the MP compartment is associated with the hyperactivation of cytokine signaling, we performed phos-flow analysis in cells were first serum-and cytokine-deprived for 2 h before fixation and permeabilization to measure phospho-ERK1/2 (p-ERK1/2) and p-STAT5 levels ( Figure 2d and Supplementary Figure S7A ). As expected, the ERK pathway was hyperactivated in both populations of cells from Nras G12D/+ , Nras Q61R/+ and Nras G12D/G12D mice, while p-STAT5 levels in these cells were comparable to those in control cells. and Nras G12D/G12D mice showed significant hyperactivation of ERK1/2 in response to GM-CSF, but no or marginal hyperactivation in response to IL-3 (Figure 2e) Figure S7B) .
Notably, despite the more potent leukemogenic activity of the Nras Q61R allele, NRAS Q61 mutations are less frequent than G12 mutations in hematopoietic malignancies (Supplementary Figure S1) . One possible explanation of this observation is that NRAS G12 mutations could be initiating events in leukemogenesis or acquired during leukemia progression, whereas Q61 mutations are more likely to serve as secondary events during leukemia development. This possibility is supported by the observation that NRAS G12 mutations are identified in both chronic and acute stages of hematopoietic malignancies, whereas Q61 mutations are enriched in acute or more advanced stage of these diseases. 3 In summary, our data indicate that endogenous Nras Q61R/+ induces an increase of Nras-GTP and cytokine-evoked signaling, which is intermediate between Nras G12D/+ and Nras G12D/G12D . Figure 1 . Somatic activation of Nras Q61R/+ leads to intermediate leukemia phenotypes between Nras G12D/+ and Nras G12D/G12D . (a, b) Six-to 7-week-old control (C), Nras G12D/+ (G/+), Nras Q61R/+ (Q/+) and Nras G12D/G12D (G/G) mice were injected with polyinosinic-polycytidylic acid (pI-pC) and were killed on day 5 for analysis as described in Methods in Supplementary Information. (a) Whole-cell lysates (WCLs) were extracted from total bone marrow cells and assayed for expression levels of different Ras isoforms. Ras-GTP was affinity purified from WCLs using a GST fusion with the Ras binding domain of Raf (Raf RBD) immobilized on agarose beads. Different Ras isoforms and total Ras bound with GTP were analyzed using western blot analyses. The results were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The ratios of Ras-GTP/Ras in control cells are arbitrarily set at 1. (b) Quantification of spleen weight. (c) Kaplan-Meier survival curves were plotted against days after first pI-pC injection. P-values were determined using the log-rank test. (d) Disease incidences of moribund mice. The results are presented as mean ± s.d. *P o0.05, ***P o0.001.
Therefore, the leukemogenic activity of Nras Q61R/+ is stronger than Nras G12D/+ , but weaker than Nras G12D/G12D . The simplicity of breeding and the intermediate leukemogenic activity of the Nras Q61R/+ model make it ideal to test whether additional genetic mutations might accelerate or alleviate its leukemia phenotypes. In addition, given the prevalence of NRAS Q61 mutations in certain hematopoietic malignancies (for example, plasma cell myeloma), the conditional Nras Q61R allele, when combined with appropriate transgenic Cre lines, could be used to physiologically mimic these specific diseases in vivo.
Methods are described in Supplementary Information. The colonies were counted after 7 days in culture. (d, e) Whole bone marrow cells were serum-and cytokine-starved for 2 h at 37°C. Levels of p-ERK1/2 were measured using phospho-flow cytometry (d). Cells were then stimulated with different concentrations of mGM-CSF or mIL-3 for 10 min at 37°C. Levels of p-ERK1/2 were measured using phospho-flow cytometry (e). Non-neutrophil bone marrow cells were gated for data analysis. MPs are enriched in Lin − /low c-Kit + cells, whereas myeloid precursors are enriched in Lin − /low c-Kit − cells. To quantify the activation of ERK1/2, median intensities of p-ERK1/2 at different GM-CSF or IL-3 concentrations are compared with their respective control cells at 0 ng/ml, which is arbitrarily set at 1. Representative plots from one experiment are shown. The results are presented as mean ± s.d. Asterisks of different colors represent P-values when comparing corresponding group with control. *Po0.05, **Po0.01 and ***Po0.001.
